Evolus, Inc. (NASDAQ:EOLS) Stake Raised by AQR Capital Management LLC

AQR Capital Management LLC grew its holdings in shares of Evolus, Inc. (NASDAQ:EOLS) by 33.3% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 72,007 shares of the company’s stock after buying an additional 17,971 shares during the period. AQR Capital Management LLC owned 0.12% of Evolus worth $781,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Quest Partners LLC acquired a new position in Evolus in the second quarter worth approximately $43,000. Sierra Summit Advisors LLC purchased a new position in Evolus in the 4th quarter worth about $119,000. Profund Advisors LLC acquired a new stake in Evolus during the 2nd quarter worth about $130,000. China Universal Asset Management Co. Ltd. lifted its stake in Evolus by 65.8% during the first quarter. China Universal Asset Management Co. Ltd. now owns 10,969 shares of the company’s stock valued at $154,000 after buying an additional 4,355 shares in the last quarter. Finally, Arizona State Retirement System grew its position in Evolus by 9.4% during the 2nd quarter. Arizona State Retirement System now owns 14,603 shares of the company’s stock worth $158,000 after purchasing an additional 1,253 shares in the last quarter. Institutional investors own 90.69% of the company’s stock.

Insider Activity

In related news, CFO Sandra Beaver sold 3,276 shares of the business’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $14.98, for a total transaction of $49,074.48. Following the transaction, the chief financial officer now directly owns 148,502 shares of the company’s stock, valued at approximately $2,224,559.96. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CFO Sandra Beaver sold 3,276 shares of the business’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $14.98, for a total value of $49,074.48. Following the completion of the sale, the chief financial officer now directly owns 148,502 shares in the company, valued at $2,224,559.96. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the business’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $15.85, for a total value of $89,251.35. Following the completion of the sale, the chief marketing officer now owns 82,375 shares of the company’s stock, valued at $1,305,643.75. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 6.10% of the company’s stock.

Evolus Stock Performance

Shares of Evolus stock opened at $16.90 on Monday. The firm has a 50 day simple moving average of $15.49 and a 200 day simple moving average of $13.37. The firm has a market cap of $1.06 billion, a P/E ratio of -16.10 and a beta of 1.31. Evolus, Inc. has a fifty-two week low of $7.44 and a fifty-two week high of $17.70. The company has a debt-to-equity ratio of 6.26, a current ratio of 2.92 and a quick ratio of 2.67.

Evolus (NASDAQ:EOLS) last issued its earnings results on Wednesday, July 31st. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.02). The business had revenue of $66.91 million for the quarter, compared to analysts’ expectations of $65.06 million. Sell-side analysts predict that Evolus, Inc. will post -0.64 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on EOLS shares. HC Wainwright reiterated a “buy” rating and set a $27.00 price objective on shares of Evolus in a report on Thursday, October 3rd. Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 price objective on shares of Evolus in a research note on Friday, September 13th. Barclays raised their target price on Evolus from $16.00 to $20.00 and gave the company an “overweight” rating in a report on Friday, September 13th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Evolus in a report on Monday, September 16th.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.